UPDATE: Dominick & Dominick Initiates Sarepta Therapeutics at Market Perform; Catalysts Remote

Dominick & Dominick initiated coverage on Sarepta Therapeutics

with a Market Perform rating. Dominick & Dominick noted, "Sarepta Therapeutics, formerly known as AVI Biopharma, is developing RNA-based medicines that treat infectious and rare diseases at the molecular level. While we are enthusiastic regarding the recent encouraging data generated by the company's lead clinical program, eteplirsen (formerly known as AVI-4658) for Duchenne's Muscular Dystrophy (DMD), value-driving catalysts will be rekindled in 2014. As such, we believe the shares will mark time for the foreseeable future." Sarepta Therapeutics closed at $31.01 on Monday.